Answers are grounded in this paper and cite their sources.
Real-world use of long-acting injectable antipsychotics (LAIs) for schizophrenia varies across health systems, but its worldwide utilization and sources of heterogeneity remain uncertain. We aimed to estimate LAI utilization and examine study-level moderators. We conducted a PRISMA 2020-compliant systematic review and meta-analysis under a registered protocol (CRD420251171257). Six databases were searched from inception to July 2026 for observational studies reporting an LAI numerator and corresponding denominator. Logit-transformed proportions were pooled using restricted maximum-likelihood random-effects models with Knapp–Hartung inference. Prediction intervals, subgroup analyses, exploratory meta-regression, leave-one-out and sampling-scope sensitivity analyses, and Egger’s test were performed. Twenty-six studies contributed 27 analytical estimates comprising 1 619 602 participants and 258 382 LAI users. The pooled utilization proportion was 18.7% (95% confidence interval, 15.3%–22.8%), with a 95% prediction interval of 6.0%–45.5% and substantial heterogeneity (I² = 99.96%). Utilization was 26.0% in Europe, 14.3% in Asia, and 15.7% in North America (P for subgroup difference = 0.016). Geographic region and study-level male proportion showed nominal univariable associations, but neither remained significant after false-discovery-rate correction across 13 moderator tests. Sensitivity analyses were stable, and Egger’s test provided no evidence of asymmetry (P = 0.578). Approximately one in five participants received an LAI, but utilization was highly setting-dependent. The pooled estimate should be interpreted as a cross-setting average rather than a treatment target, and the moderator findings as hypothesis-generating.
No takes yet. Share an insight, caveat, or question.
陈小宝 et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: